Active Biotech
Active Biotech Interim Report Q1 2023
MAR
FIRST QUARTER IN BRIEF
- Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30)
- Active Biotech published new preclinical data highlighting the mechanisms behind the anti-tumor activity of tasquinimod in hematological malignances
- New preclinical data on naptumomab published
EVENTS AFTER THE END OF THE PERIOD
- Safety and preliminary activity of naptumomab in combination with durvalumab presented at AACR 2023 (April 19)
- New clinical data on tasquinimod in multiple myeloma to be presented at ASCO 2023 (April 27)
FINANCIAL SUMMARY
SEK M | Jan-Mar | Full year | |
2023 | 2022 | 2022 | |
Net sales | - | - | - |
Operating profit/loss | -11.8 | -15.3 | -57.9 |
Profit/loss after tax | -11.5 | -15.7 | -58.4 |
Earnings per share (SEK) | -0.04 | -0.07 | -0.25 |
Cash and cash equivalents (at close of period) | 30.2 | 37.8 | 41.8 |
The report is also available at www.activebiotech.com
Datum | 2023-05-04, kl 08:30 |
Källa | MFN |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!